Genmab A/S (NASDAQ:GMAB) Q4 2024 Earnings Call Transcript
Operator: Hello, and welcome to the Genmab Full Year 2024 Financial Results Conference Call. As a reminder, this conference call is being recorded.
Genmab A/S (GMAB)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Citadel Investment Group Ken Griffin | 3,092,144 | $64,533,045 | +138% | 0.01% |
| 2. | Orbis Investment Management William B. Gray | 2,815,562 | $58,760,779 | +68% | 0.31% |
| 3. | Deep Track Capital David Kroin | 2,000,000 | $41,740,000 | 1.55% | |
| 4. | Renaissance Technologies Jim Simons | 1,926,150 | $40,198,750 | +8% | 0.05% |
| 5. | Two Sigma Advisors John Overdeck And David Siegel | 1,653,500 | $34,508,545 | +169% | 0.07% |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 14,935,224 | $311,698,125 | 0.1% | |
| 2. | 4,198,452 | $87,621,692 | 0% | |
| 3. | 2,805,881 | $58,558,785 | 0% | |
| 4. | 2,570,909 | $53,397,783 | 0.01% | |
| 5. | 2,243,392 | $46,819,589 | 0.31% |
News See All
Why Genmab (GMAB) and Sonic Automotive (SAH) Are Advancing Today
Leerink does not expect Johnson & Johnson (JNJ) to exercise its option to develop GMAB's GEN3014, a treatment candidate for relapsed/refractory multiple myeloma patients.
12 Best Healthcare Stocks to Buy According to Analysts
McKinsey reported that, since 2019, the US healthcare industry witnessed significant financial pressure.
12 High Growth International Stocks to Invest in Now
On January 15, Jurrien Timmer, Director of Global Macro at Fidelity Management & Research Company shared his outlook for 2025.
10 High Growth Healthcare Stocks to Invest in Now
During lean economic times, investing in healthcare stocks is generally regarded as defensive.
10 Worst Performing Healthcare Stocks in 2024
The healthcare industry remains a vital and resilient sector which is driven by advancements in technology, increasing global demand, and an aging population.
10 Worst Performing Biotech Stocks in 2024
Biotechnology stocks are among the most volatile in the market due to their high risk.
12 High Growth Large Cap Stocks to Buy Now
BlackRock highlighted that its portfolio managers are broadly optimistic about US equities.
Genmab A/S (NASDAQ:GMAB) Q3 2024 Earnings Call Transcript
Operator: Hello, and welcome to Genmab's Financial Results Conference Call for the First Nine Months of 2024. As a reminder, this conference call is being recorded.
12 Most Profitable Growth Stocks To Invest In
After the September inflation report, the market did feel a slight bit of panic but it seems to be fading away.
Billionaire Hedge Funds
